Oxygen for Preterm Infants; Top-Down Therapy in Crohn's
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
In a recent study published in JAMA, researchers found that the IV administration of a compound called loberamisal, which targets two different repair pathways in the body, improved outcomes in stroke patients who did not qualify for thrombolytic therapy or thrombectomy. The study included just under 1,000 patients in China, half of whom received routine care and the other half received loberamisal for 10 days after their stroke.
Those who received loberamisal had a 70% recovery rate compared to only 56% in the placebo group. There were no serious adverse events reported. However, it is unclear how this would compare to thrombolysis in stroke patients.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
